3TC: Expanded Access Will Be Limited


Starting April 3, Glaxo is limiting enrollment in its 3TC
expanded access program to 350 new patients per week in North
America. In late March, 800 per week or more had been
enrolling.

Those who qualify for the program will be placed on a waiting
list, first come first serve. This means that number 351 in
one week will be number 1 the next. Presumably the wait will
be relatively short for the next month or two, and then will
grow longer.

According to Glaxo, this change is needed because of limited
drug supplies. Glaxo hopes that new supplies will be
available by the fall, when production facilities have been
upgraded.

It is generally believed that 3TC will be approved by early
1996.